FDA approved new sickle cell treatment based on clincal trial resutls from UTHSC’s Kenneth Ataga, MD
On Dec. 2, 2019, the U.S. Food and Drug Administration (FDA) announced it had approved the drug crizanlizumab based on the results of a clinical trial led by Kenneth Ataga, MD, of the Center for Sickle Cell Disease at the University of Tennessee Health Science Center.
Tags:
Source: The University of Tennessee Health Sciences Center News
Credit:
